Dicerna Pharmaceuticals, Inc. Company Review & Valuation

DRNA
Nasdaq
Latest Price
19.91USD
Market Capitalization
1.55bUSD

About Dicerna Pharmaceuticals, Inc.

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of pharmaceuticals for the treatment of rare, viral infectious, chronic liver, and cardiovascular diseases.

Its development programs include DCR-PHXC for the treatment of primary hyperoxaluria; DCR-HBVS for the treatment of chronic hepatitis B virus infection; and DCR-PCSK9 to treat hypercholesterolemia.

The company has a collaborative research and license agreement with Boehringer Ingelheim International GmbH; a research collaboration and license agreement with Kyowa Hakko Kirin Co., Ltd.; and a license agreement with City of Hope.

Dicerna Pharmaceuticals, Inc.

was founded in 2006 and is headquartered in Cambridge, Massachusetts.

Industry
Biotechnology
HQ Location
Cambridge, Massachusetts

Stock Price

Price data not available for Dicerna Pharmaceuticals, Inc..

Performance

Please login or create a free account to view the contents of this section.

Financial Reports

Please login or create a free account to view the contents of this section.

Similar Companies

back to top

Valuu.io

Valuu provides insights and tools for self-directed stock investors. It enables you to easily find, valuate and track your stock investments with the help of reliable financial data and transparent analysis tools.

Disclaimer: This website is a data portal, which aggregates information about public companies. It is not a stock broker and does not give advice concerning specific investment decisions or tax or legal advice. All data is provided "as-is" with no guarantee for correctness and/or completeness. All company names, logos, and brands are intellectual property of their respective owners. The use of them is for editorial purposes only and does not imply any affiliation or endorsement.
© 2019-2021 Valuu Analytics Sàrl